What Apotex Inc. does

Apotex Inc., operating as Apotex Health Corp. since its June 2026 IPO on the Toronto Stock Exchange (TSX: APTX), is a Canadian-based global pharmaceutical company founded in 1974 by Dr. Barry Sherman. The company operates four product divisions: Generics (approximately 460 products across ~70 countries, including oral solid doses, injectables, suspensions, sprays, and inhalers), Biosimilars through wholly owned subsidiary Apobiologix (with leading oncology biosimilars including Grastofil, Lapelga, Bambevi, and Toripalimab in Canada), Innovative and Specialty Medicines through Searchlight Pharma (65+ branded products), and Consumer Health (vitamins, supplements, and natural health products through CanPrev, Orange Naturals, and Cyto-Matrix). Apotex also operates DISpedia, a drug information service for healthcare professionals, and the Apotex Global Health Access Fund for health equity programs.

Apotex serves a B2B customer base including healthcare providers, hospitals, pharmacies, payers, and government health programs, with a sales-led and channel-partner distribution model reaching approximately 75 countries. The company holds the #1 position in Canadian prescription volume, top-five status in the US generics market, and #4 in Mexico's private generics market. Manufacturing is vertically integrated across six world-class finished-dose manufacturing sites plus three API sites in Canada, the United States, Mexico, and India, with approximately 25 billion finished doses produced annually. R&D investment exceeds $2 billion over the past decade, yielding dozens of new product launches each year.

The business model is unit-pricing revenue from high-volume generic and specialty product sales, with pricing negotiated through healthcare systems, pharmacy benefit managers, and government drug programs rather than publicly disclosed. In July 2026, Apotex acquired Cumberland Pharmaceuticals' U.S. branded businesses for $100 million, secured an amended $1.2 billion credit facility, and received an inaugural BBB (low) investment-grade rating from Morningstar DBRS. The company employs 6,000+ team members globally and has a 20-year partnership with Health Partners International Canada supporting medicine donations to more than 33 million people across 100 countries.

Name

Apotex Inc.

Legal name

Apotex Inc.

Website

https://apotex.com

Company type

Public

Founded year

1974

Operating status

Operating

Short description

Apotex Health Corp. (TSX: APTX) is a Canadian-based global pharmaceutical company manufacturing generics, biosimilars, specialty medicines, and consumer health products. It serves hospitals, pharmacies, and payers across approximately 75 countries from six manufacturing sites producing 25 billion doses annually.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Biosimilar medicines
• Specialty branded drugs
• Consumer health products
• Active pharmaceutical ingredients

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceuticals: Sale of generic medicines including oral solid doses, suspensions, capsules, injectables, sprays, powders, inhalers, and drops. ~460 generic products distributed across ~70 countries. Revenue from prescription volume and market share in Canada, US, and Mexico.
2. Innovative & Specialty Medicines: Branded pharmaceutical products through Searchlight Pharma division. Over 65 branded products in various therapeutic areas providing breakthrough treatments.
3. Biosimilars: Biosimilar medicines through Apobiologix. High-quality, cost-effective biologic treatments beginning with oncology and expanding into other high-impact therapeutic areas.
4. Consumer Health Products: Over-the-counter and natural health products through brands including CanPrev, Orange Naturals, and Cyto-Matrix. Vitamins, supplements, and natural health products designed by licensed practitioners.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Apotex is a vertically integrated global pharmaceutical manufacturer that develops, produces, and distributes approximately 460 generic pharmaceutical products across ~70 countries. The company's portfolio spans generics, biosimilars (through Apobiologix), innovative branded specialty medicines (through Searchlight Pharma), and consumer health products (CanPrev, Orange Naturals, Cyto-Matrix). With six world-class manufacturing sites producing approximately 25 billion finished doses annually, Apotex holds the #1 position in Canadian prescription volume and ranks in the top 10 in the U.S. generics market.

Product overview

Apotex Inc. is a Canadian-based global pharmaceutical company offering a diversified portfolio of healthcare products organized into four core divisions: Generics (approximately 460 generic pharmaceutical products distributed across ~70 countries, #1 in Canadian prescription volume, top 10 in US, #4 in Mexico's private generics market), Biosimilars through Apobiologix (leading oncology biosimilars including Grastofil, Lapelga, Bambevi, and Toripalimab), Innovative & Specialty Medicines through Searchlight Pharma (65+ branded products targeting specialty care), and Consumer Health (vitamins, supplements, and natural health products through CanPrev, Orange Naturals, and CytoMatrix brands). The company also provides drug information services through DISpedia and operates the Apotex Global Health Access Fund for health equity initiatives. With manufacturing capacity of approximately 25 billion finished doses annually across six facilities, Apotex serves markets in ~70 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Apobiologix: Makes advanced biologic treatments more accessible through high-quality biosimilars in oncology and emerging areas. Products include Grastofil, Lapelga, Bambevi, and Toripalimab.
• Searchlight Pharma
• CanPrev
• Orange Naturals
• Cyto-Matrix

Products and services

• Generic Pharmaceuticals Approximately 460 generic pharmaceutical products including oral solid doses, suspensions, capsules, injectables, sprays, powders, inhalers, and drops, distributed across ~70 countries for hospitals, pharmacies, and healthcare systems.
• Biosimilars (Apobiologix) High-quality, cost-effective biosimilar medicines developed and commercialized through Apobiologix, with leading positions in oncology biosimilars and expansion into other therapeutic areas.
• Innovative and Specialty Medicines (Searchlight Pharma) More than 65 branded pharmaceutical products targeting unmet needs in specialty care across various therapeutic areas including dermatology, allergy, pain management, ophthalmology, and women's health.
• Consumer Health Products (CanPrev, Orange Naturals, Cyto-Matrix) Vitamins, supplements, and natural health products designed by licensed practitioners for optimal health and well-being, distributed through CanPrev, Orange Naturals, and Cyto-Matrix brands.
• Generic Infuvite Adult and Pediatric Injection Four configurations of generic equivalents of Infuvite Pediatric and Adult Injection products launched into the U.S. hospital market, with two configurations receiving Competitive Generic Therapy (CGT) exclusivity.
• SEVMIA (Generic Semaglutide) Generic semaglutide for chronic weight management; Apotex was the first company to receive Health Canada approval for this product.
• Sitagliptin Tablets and Sitagliptin/Metformin Hydrochloride Tablets Generic sitagliptin tablets and sitagliptin/metformin hydrochloride combination tablets eligible for 180-day shared exclusivity in the U.S. market.

Quantifiable outcome

• $11 billion+ in healthcare system savings in Canada in the last five years
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core, adjacent and strategic.

• Orbicular Pharmaceutical Technologies Pvt. Ltd.coreTechnology or Integration · 8 July 2026Collaboration for development of generic Infuvite Adult and Pediatric Injection products. Orbicular provides technical expertise in complex generic and specialty pharmaceutical product development.
• Gland Pharma LimitedcoreTechnology or Integration · 8 July 2026Partnership for development and manufacturing of generic Infuvite products. Gland Pharma is a leading injectable-focused pharmaceutical company specializing in sterile injectable products.
• Cumberland PharmaceuticalscoreStrategic or Co-development Partner · 6 May 2026Strategic transaction to integrate Cumberland's U.S. branded businesses into Apotex for $100 million in cash. Completed July 1, 2026. This deal marks a major shift for Apotex to expand its branded pharmaceutical portfolio.
• Health Partners International Canada (HPIC)coreStrategic or Co-development Partner · 1 January 200520-year partnership for global medicine donation program. HPIC has helped more than 33 million people across 100 countries gain access to medications. Apotex has provided over $45 million in medicine donations.
• ApobiologixcoreStrategic or Co-development PartnerApotex subsidiary focused on biosimilar development. Leading in oncology biosimilars with top-selling products in Canada including Grastofil, Lapelga, Bambevi, and Toripalimab.
• Searchlight PharmacoreStrategic or Co-development PartnerApotex specialty pharma division focused on innovative branded pharmaceuticals. Expanding portfolio of pain management and allergy products.
• CanPrevadjacentStrategic or Co-development PartnerConsumer health brand under Apotex offering vitamins, supplements, and natural health products designed by licensed practitioners.
• Orange NaturalsadjacentStrategic or Co-development PartnerConsumer health brand offering natural health products distributed through established channels.
• Cyto-MatrixadjacentStrategic or Co-development PartnerConsumer health brand focused on practitioner-formulated vitamins and supplements.
• Formosa PharmastrategicStrategic or Co-development PartnerPartnership to expand into new markets with branded pharmaceuticals.
• HarrowstrategicStrategic or Co-development PartnerPartnership to enter Canadian market through Apotex for ophthalmology products including IHEEZO and other eye care treatments.

Scale indicators20 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Endo International: Specialty and generics pharmaceutical company with significant US footprint across injectables, generics, and branded specialty. Comparable in US generics and specialty portfolio breadth.
• Sandoz: Novartis spin-off and #2 global generics player with strong small-molecule generics and biosimilars businesses. Directly comparable as a vertically integrated generic and biosimilar manufacturer serving multiple geographies.
• Sun Pharmaceutical Industries: India-based global generic pharmaceutical manufacturer with strong US and emerging market presence. Comparable in API manufacturing capability, generics portfolio breadth, and specialty branded expansion.
• Viatris: Global generics and specialty pharmaceutical company formed from Mylan-Upjohn combination. Comparable in scale and breadth across generics, branded specialty, and biosimilars with similar global distribution model.
• Dr. Reddy's Laboratories: Indian global pharmaceutical company with integrated API-to-generics operations across North America, Europe, and emerging markets. Comparable in vertically integrated generics, biosimilars, and specialty pharma.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with strong US generics presence and growing European footprint. Comparable in scale of US generics business, API integration, and emerging biosimilars investments.
• Hikma Pharmaceuticals: Generic and specialty pharmaceutical company with strong US hospital injectables presence and MENA regional leadership. Comparable in hospital/institutional generics focus and specialty branded portfolio.
• Teva Pharmaceutical Industries: World's largest generic pharmaceuticals manufacturer with extensive oral solid dose, API, and biosimilars capabilities across global markets. Most directly comparable peer given scale, broad generic portfolio, and biosimilars presence.
• Lupin Pharmaceuticals: India-headquartered global generics company with significant US and emerging market presence. Comparable in oral solid dose generics manufacturing, complex generics focus, and biosimilars pipeline.

Regional players

• Bausch Health: Canadian-headquartered specialty pharmaceutical company with diversified branded generics, branded pharma, and consumer health businesses. Comparable as a major Canadian-headquartered pharmaceutical peer with similar portfolio breadth and product diversification.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=35g_uym0leq

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apotex Inc.